• BioPearl™ Microspheres Loaded With Doxorubicin: Prospective, Single Arm, Multi-centre Post-market Follow-up Study.

  NCT04231929

  WithdrawnInterventionalNot ApplicableUpdated Mar 28, 2022
• LifePearl-Doxo Pharmacokinetic (PK) Study

  NCT02548780

  CompletedInterventionalNot ApplicableUpdated Jan 27, 2020
• Chemoembolization Using LifePearl Polyethylene Glycol Drug Eluting Microspheres With Doxorubicin in HCC

  NCT03734068

  Unknown statusObservationalUpdated Feb 21, 2019
• HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

  NCT01387932

  TerminatedInterventionalPhase 3Updated Nov 30, 2021
• Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation

  NCT00261378

  CompletedInterventionalPhase 2Updated Jul 21, 2021
• Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma

  NCT01891539

  Unknown statusObservationalUpdated Feb 27, 2019

ClinicalTrials.gov ID

NCT05911633

Lead Sponsor

Terumo Europe N.V.INDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

50Estimated

Last Update Posted

Jul 10, 2026Actual

Start Date

Feb 27, 2024Actual

Primary Completion Date

Sep 30, 2026Estimated

Completion Date

Dec 30, 2027Estimated

Official Title

BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC): Prospective, Single Arm, Multi-center, Post-Market Clinical Follow-up (PMCF) Study

Brief Summary

The primary objective of the study is to confirm safety and technical success of BioPearl™ microspheres loaded with Doxorubicin in the treatment of unresectable hepatocellular carcinoma (HCC). The secondary objective of the study is to investigate the efficacy of BioPearl™ microspheres loaded with Doxorubicin in the treatment of subjects with unresectable HCC.

Detailed Description

This is a prospective, single arm, multi-centre, post-market clinical follow-up study to further assess safety and efficacy in 50 subjects with unresectable HCC treated with BioPearl™ microspheres loaded with Doxorubicin. All subjects will undergo clinical follow-up until disease progression and/or next treatment option, after which subjects will be followed for survival. Subjects will be followed up to a maximum of 18 months. An intermediate analysis will take place during enrollment period on safety and technical success to support regulatory requirements.

• Hepatocellular Carcinoma Non-resectable

• BioPearl™

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Subject is at least 18 years old
2. Subject with HCC confirmed by histology or according to the latest applicable version of EASL (the European Association for the Study of the Liver) criteria
3. Subject with tumor(s) < 5 cm and within the up-to-7 criteria: the sum of the diameter of the largest tumor (in cm) and the number of tumors must be ≤ 7.0
4. Subject with BCLC (Barcelona Clinic Liver Cancer) Stage A or B classification who is not a candidate for curative treatment at the time of study inclusion
5. Subject with treatment failure/recurrence after a prior resection/ablation is permitted, with the exception of recurrence in the segment of a prior thermal ablation
6. WHO (World Health Organization) or ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1
7. Subject deemed treatable in one session for initial treatment
8. Normal liver or compensated cirrhosis with preserved liver function (Child-Pugh Class A)
9. Total bilirubin ≤ 2.0 mg/dl
10. Adequate bone marrow function: Hemoglobin ≥ 9g/dl, absolute neutrophil count ≥ 1.0 x 109/L, platelet count ≥ 75 x 109/L
11. Subject with no ascites or with minor ascites controlled by sodium dietary restrictions (subject receiving diuretic treatment or paracentesis is not eligible)
12. Adequate renal function: serum creatinine < 1.5 X ULN (Upper Limit of Normal)
13. Subject has provided written informed consent
14. Subjects of childbearing/reproductive potential should use adequate birth control measures, during the study treatment period until survival follow-up

Exclusion Criteria:

1. Subject previously treated with any systemic therapy for HCC

2. Subject previously treated with intra-arterial loco-regional therapy for HCC

3. Eligible for curative treatment at the time of study inclusion

4. Recurrence in the segment of a prior thermal ablation

5. Advanced liver disease: Child-Pugh's B-C class or active gastrointestinal bleeding, encephalopathy

6. Advanced tumoral disease: BCLC class C or D (vascular invasion - even segmental, extra-hepatic spread or cancer-related symptoms performance status >1)

7. History of another primary tumor. Exceptions include:

   A. Malignancy treated with curative intent ≥ 5 years before inclusion and with no known active disease

   B. Malignancy which occurred < 5 years before, not active and not expected to recur or be clinically relevant in the next 5 years

8. Subject with history of biliary tree disease or biliary dilatation

9. Portal vein thrombosis, porto-systemic shunt, hepatofugal blood flow or absent portal blood flow in the liver area to be treated

10. Contraindication to multiphasic CT and MRI (e.g. allergy to contrast media)

11. Any other contraindication for embolization procedure or Doxorubicin treatment

12. Subject is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints

    Note: Trials requiring extended follow-up for products that were investigational, but have become commercially available since then, are not considered investigational trials

13. In the Investigator's opinion subject has (a) co-morbid condition(s) that could limit the subject's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study

14. Pregnant or breast-feeding woman

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Terumo Europe N.V.INDUSTRY

geert.maleux@uzleuven.be0032 16 34 75 78